Sanofi (SNY) & Regeneron (REGN) Report Dupixent (dupilumab) Showed Positive Phase 3 Results in Adolescents with Inadequately Controlled Moderate-to-Severe Atopic Dermatitis

May 16, 2018 5:50 AM EDT Send to a Friend

Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis LEARN MORE

Member Login